The effects of galangin in prepulse inhibition test and experimental schizophrenia models.

Creative Commons License

Kaygisiz B., Aydin Ş., Yildirim E., Musmul A., Erol K., Kilic F. S.

Acta neuropsychiatrica, cilt.34, ss.37-46, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 34
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1017/neu.2021.33
  • Dergi Adı: Acta neuropsychiatrica
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Abstracts in Social Gerontology, EMBASE, MEDLINE, Psycinfo
  • Sayfa Sayıları: ss.37-46
  • Anahtar Kelimeler: cognitive function, flavonoid, experimental animal models, prepulse inhibition, schizophrenia, ANIMAL-MODELS, ALLOSTERIC MODULATORS, CHOLINERGIC NEURONS, STARTLE RESPONSE, INDUCED DEFICITS, RECEPTOR, GALANTAMINE, PROFILE, RATS, ACETYLCHOLINESTERASE
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective:Acetylcholinesterase inhibitors are the focus of interest in the management of schizophrenia. We aimed to investigate the effects of acute galangin administration, a flavonoid compound with acetylcholinesterase inhibiting activity, on schizophrenia-associated cognitive deficits in rats and schizophrenia models in mice. Methods:Apomorphine-induced prepulse inhibition (PPI) disruption for cognitive functions, nicotinic, muscarinic, and serotonergic mechanism involvement, and brain acetylcholine levels were investigated in Wistar rats. Apomorphine-induced climbing, MK-801-induced hyperlocomotion, and catalepsy tests were used as schizophrenia models in Swiss albino mice. The effects of galangin were compared with acetylcholinesterase inhibitor donepezil, and typical and atypical antipsychotics haloperidol and olanzapine, respectively. Results:Galangin (50,100 mg/kg) enhanced apomorphine-induced PPI disruption similar to donepezil, haloperidol, and olanzapine (p < 0.05). This effect was not altered in the combination of galangin with the nicotinic receptor antagonist mecamylamine (1 mg/kg), the muscarinic receptor antagonist scopolamine (0.05 mg/kg), or the serotonin-1(A) receptor antagonist WAY-100635 (1 mg/kg) (p > 0.05). Galangin (50,100 mg/kg) alone increased brain acetylcholine concentrations (p < 0.05), but not in apomorphine-injected rats (p > 0.05). Galangin (50 mg/kg) decreased apomorphine-induced climbing and MK-801-induced hyperlocomotion similar to haloperidol and olanzapine (p < 0.05), but did not induce catalepsy, unlike them. Conclusion:We suggest that galangin may help enhance schizophrenia-associated cognitive deficits, and nicotinic, muscarinic cholinergic, and serotonin-1(A) receptors are not involved in this effect. Galangin also exerted an antipsychotic-like effect without inducing catalepsy and may be considered as an advantageous antipsychotic agent.